AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ARS Pharmaceuticals, Inc. Director's Dealing 2024

Dec 12, 2024

32159_dirs_2024-12-12_6d765b6d-a474-4883-9526-af9432c33388.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARS Pharmaceuticals, Inc. (SPRY)
CIK: 0001671858
Period of Report: 2024-12-10

Reporting Person: Chakma Justin (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-12-10	Common Stock	M	50000	$0.84	Acquired	186380	Direct
2024-12-10	Common Stock	S	50000	$13.1525	Disposed	136380	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-12-10	Stock Option (Right to Buy)	$0.84	M	50000	Disposed	2029-07-04	Common Stock (50000)	Direct

Footnotes

F1: The weighted average sale price for the transaction reported was $13.1525, and the range of prices were between $12.95 and $13.42. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

F2: Immediately exercisable.